Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 88, Issue 1, Pages 168-177Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2013.04.003
Keywords
CS1; CRACC; SLAM; Multiple myeloma; Elotuzumab; EAT-2; SAP
Categories
Funding
- Canadian Institute of Health Research
- Canada Research Chair program
- Bristol-Myers Squibb
- Joseph-Paulin Doctoral Scholarship
Ask authors/readers for more resources
Signaling lymphocytic activation molecule (SLAM) family receptors have been implicated in normal immunity, immunodeficiencies and autoimmunity. CS1 (also known as CRACC, CD319 and SLAMF7) is a member of the SLAM family expressed on several normal hematopoietic cell types. It is also highly and nearly universally expressed on multiple myeloma (MM) cells. This review focuses on the biology of CS1, both in normal hematopoietic cells and in MM cells. It also discusses the preclinical and clinical data on the use of a humanized anti-CS1 monoclonal antibody, elotuzumab, for the treatment of MM. Based on current knowledge, CS1 is a compelling new target for the treatment of MM. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available